All about CHF.ppt
-
Upload
yuhumaqyu6841 -
Category
Documents
-
view
217 -
download
0
Transcript of All about CHF.ppt
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 1/180
CHRONIC CONGESTIVE HEART
FAILURE
A Comprehensive Overview on Diagnosis and Treatment
Dr. Cholid Tri Tjahjono, MKes, SpJP
Faculty of Medicine
Brawijaya University Malang
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 2/180
Introduction
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 3/180
Definition : Heart Failure
“ The si tuat ion when the heart is incapable of
maintaining a cardiac ou tpu t adequate to
accommodate metabo l ic requi rements and the
venous return .“ E. Braunwald
“Pathophysiological state in which an
abnormali ty of cardiac fun ct ion is responsib le
for the fai lure of the heart to pump b lood at a rate commensu rate wi th the requ i rements of
the metabol izing t issues.” Euro Heart J ; 2001. 22: 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 4/180
DEFINITION OF HEART FAILURE. Criteria 1 and 2 should be fulfilled in all cases
1. Symptoms of heart failure(at rest or during exercise)
And
2. Objective evidence of cardiac dysfunction(at rest)
And(in cases where the diagnosis is in doubt)
3. Response to treatment directed towards heartfailure
Task Force Report. Guidelines for the diagnosis and treatment of chronic heart failure.
European Society of Cardiology.2001
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 5/180
EPIDEMIOLOGY
Europe
The prevalence of symptomatic HF range from 0.4-2%.
10 million HF pts in 900 million total population
USA
nearly 5 million HF pts.
±500,000 pts are D/ HF for the 1
st
time each year.Last 10 years number of hospitalizations has increased.
Nearly 300,000 patients die of HF each year.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
ACC/AHA Guidelines for the
Evaluation and Management of Chronic Heart Failure in the Adult 2001
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 6/180
DESCRIPTIVE TERMS in HEART FAILURE
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1528
Acute vs Chronic Heart Failure
Systolic vs Diastolic Heart Failure
Right vs Left Heart Failure
Mild , Moderate, Severe Heart Failure
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 7/180
New York Heart Association (NYHA)Classification of Heart Failure
Class – INo limitation : ordinary physical exercise doesnot cause undue fatigue, dyspnoea or palpita-tions.
Class–
II
Slight limitation of physical activity : comfor-
table at rest but ordinary activity results infatigue, dyspnoea, or palpitation.
Class - IIIMarked limitation of physical activity : comfor-table at rest but less than ordinary activityresults in symptoms.
Class - IV
Unable to carry out any physical activity with-out discomfort : symptoms of heart failure arepresent even at rest with increased discomfortwith any physical activity.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1531
(Adapted from Williams JF et al., Circulation. 1995; 92 : 2764-2784)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 8/180
ACC/AHA – A New Approach To The Classification of HF
Stage Descriptions Examples
A Patient who is at high risk for developing HF but has no
structural disorder of the heart.
Hypertension; CAD; DM;rheumatic fever; cardiomyopathy.
B Patient with a structural disorder
of the heart but who has never developed symptoms of HF.
LV hypertrophy or fibrosis;
LV dilatation; asymptomatic VHD;MI.
C Patient with past or current
symptoms of HF associated with
underlying structural heart
disease.
Dyspnea or fatigue ec LV systolic
dysfunction; asymptomatic
patients with HF.
D Patient with end-stage disease Frequently hospitalized pts ; pts
awaiting heart transplantation etc
ACC/AHA Guidelines for theEvaluation and Management of Chronic Heart Failure in the Adult 2001
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 9/180
Stage A Stage B Stage C Stage D
Pts with :
• Hypertension
• CAD
• DM
• Cardiotoxins
• FHx CM
THERAPY• Treat Hypertension
• Stop smoking
•Treat lipid disorders• Encourage regular
exercise
• Stop alcohol
& drug use
• ACE inhibition
Pts with :
• Previous MI
• LV systolic
dysfunction
• Asymptomatic
Valvular disease
THERAPY• All measures under
stage A
•ACE inhibitor • Beta-blockers
THERAPY• All measures under
stage A
•Drugs for routine use:• diuretic
• ACE inhibitor
• Beta-blockers
• digitalis
THERAPY• All measures under
stage A,B and C
• Mechanical assist
device
• Heart transplantation
• Continuous IV
inotrphic infusions for
palliation
Pts who have
marked symptoms
at rest despite
maximal medical
therapy.
Pts with :
• Struct. HD
• Shortness of
breath and fatigue,
reduce exercise
tolerance
Struct.
Heart
Disease
Develop
Symp.of
HF
Refract.
Symp.of
HF at rest
Stages in the evolution of HF and recommended therapy by stage
ACC/AHA Guidelines for theEvaluation and Management of Chronic Heart Failure in the Adult 2001
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 10/180
EVOLUTION OF
CLINICAL STAGES
NORMAL
AsymptomaticLV Dysfunction
CompensatedCHF
DecompensatedCHF
No symptomsNormal exercise
Normal LV fxn
No symptoms
Normal exercise
Abnormal LV fxn
No symptomsExercise
Abnormal LV fxn
Symptoms
Exercise
Abnormal LV fxn
RefractoryCHF
Symptoms not controlled
with treatment
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 11/180
Evolution of the Concept of Heart Failure
1950 to 20001950 2000
Aetiology Hypertension CHDValvular heart dis Hypertension
Dilated CMP
Natural Course Slowly progressive Slowly progressive (remodelling)
or unpredictable and rapid( coronary event )
Understanding Hemodynamic model Neurohormonal model
Common cause Pulmonary infection Sudden deathof death Pump failure
Arrhythmia Atrial Ventricular
Treatment goal Control edema Improve quality of lifeSlowing Heart Rate + reduce mortality + reduce
hospitalization
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 12/180
Patophysiology of C H F
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 13/180
g a b c d e f g a
AO
AorticclosureAortic
pressure
Ventricular
pressure
Cross-over Atrial
pressure
MO
Heartsounds
S4
M1T1
A2P2 S3
Cardiologicsystole
a c
v
JVP
P T
ECG
P
Q S
0 800 msec
The Wiggers cycle
O p
i e ( 2 0 0 1 )
g
a b
iso
c d
iso e
f
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 14/180
Input
Block diagram of left ventricular pump performance
(Little, 2001)
Output
PULMONARY VENOUSPRESSURE
CARDIAC OUTPUT
Filling Emptying
ED volume x EFeffective =Strokevolume
Heartrate
x
Diastolic function Systolic function
LV Distensibility
RelaxationLeft atriumMitral valvePericardium
Contractility
AfterloadPreloadStructure
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 15/180
SYSTOLIC FAILURE
Normal
Normaldiastolicchamber
distensibility
Left Ventricular Volume
L e f t V
e n t r i c u l a r P r e s s u r e
Left Ventricular Volume
L e f t V
e n t r i c u l a r P r e s s u r e
DIASTOLIC FAILURE
Decreaseddiastolicchamber distensibility
PRESSURE – VOLUME CURVE OF SYSTOLIC AND DIASTOLIC FAILURE
(Zile & Brutsaert 2002)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 16/180
Abnormalrelaxation
A B
Pericardialrestraint
D
Chamber dilation
C
Increasedchamber stiffness
L e f t v e n t r i c u l a r p r e s s u r e
Left ventricular volume
Mechanisms that cause diastolic dysfunction. (Zile, 1990)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 17/180
DETERMINANTS OF
VENTRICULAR FUNCTION
STROKEVOLUME
PRELOAD
CONTRACTILITY
CARDIAC OUTPUT
HEARTRATE
- Synergistic LV contraction- LV wall integrity- Valvular competence
AFTERLOAD
F k St li L
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 18/180
Frank-Starling Law
Normal
Compensated
CHF
Normal C.O.
LVEDP
C a r d
i a c O u t p
u t
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 19/180
Ventricular Function Curve:
Frank-Starlings
Congestion
SV
Normal
LVEDV
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 20/180
Factors That Influence Ventricular
Function Curves:
LVEDV
V e n t r i c u l a r P e r f o r m a n c e
Contractile State of
the Myocardium
Cardiac
Glycosides Catecholamines
Ca ChannelBlockers (?)
ETOH
Loss of
Myocardium
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 21/180
The Pathophysiology of Heart Failure
Hurst. The Heart. Diagnosis and Management of Heart Failure.10th ed. 688
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 22/180
Pathophysiological Sequence of
CHF
Heart Failure
Inadequate Cardiac Output
( ) O2 Delivery (rest and/or exercise)
Systemic Vasoconstriction
SAS (NE)) RAAS (A-II)
() Flow to Skin, Gut,
and Renal Circulations
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 23/180
Activation of RAS and ANS
Neurohormonal Activation
Hurst. The Heart. Diagnosis and Management of Heart Failure.10th ed. 688
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 24/180
Frank-Starling Effect
Ventricular dilatation
Wall stress
O2 consumption Coronary
perfusion
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 25/180
SNS
Renin release
Angiotensin II
Vasoconstriction
Growthfactors
Hypertrophy
Apoptosis
ALDO
Fluid
accumulation
Collagen
deposition
Myofibril
necrosis
Preload Afterload
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 26/180
RBF
Renin release
Angiotensin II
Vasoconstriction
Growth
factors
Hypertrophy
Apoptosis
ALDO
Collagen deposition
Myofibril necrosis
Perfusion of Vital Organs
Na filtered
Afterload
Fluid accumulation
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 27/180
Sympathetic nervous system up-regulation
IncreasedNorepinephrine levels
DirectMyocardial toxicity
Myocyte dysfunction
Myocytenecrosis
IntracellularCa2+ overload/Energy depletion
Apoptosis
DecreasedRenal blood
flow
Activation of theRAA system
Increased HR, PVR & arteriolar vasoconstriction
Increased myocardialoxygen demand
IncreasedAngiotensin II &
Aldosteron
Na+ & waterretention
Vasoconstriction Cardiac remodeling
Cesario et.al; Reviews in cardiovascular medicine, vol 3, no.1, 2002
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 28/180
Causes of Heart Failure
Myocardial Damage or Disease
Infarction (Acute) / Ischemia
Myocarditis Hypertrophic Cardiomyopathy
Excess Load on Ventricle
Volume/ Pressure OverloadResistance to Flow into Ventricle
Cardiac Arrhythmias
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 29/180
Primary Changes in CHF
Site of Failure
BackwardFailure
ForwardFailure
Right HeartFailure
() Systemic
VenousPressure
() ejection
intoPulmonaryArtery
Left HeartFailure
() Pulmonary
Venous
Pressure
() ejection
into aorta
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 30/180
MI-INDUCED HEART FAILURE
Myocardial Damage
Contractility
Pump Performance
() SAS Drive Vasoconstriction
() Systolic Work Load
RAAS SYSTEM
FLUID RETENTION
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 31/180
Diagnosis of C H F
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 32/180
IDENTIFICATIONS OF HF PATIENTS
With a Syndrome of Decrease ExerciseTolerance
With a Syndrome of Fluid Retention
With No Symptoms or Symptoms of Another Cardiac or Non Cardiac
Disorder(MI, Arrythmias, Pulmonary orSystemic Thromboembolic Events)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 33/180
SYMPTOMS AND SIGN
Breathlessness, Ankle Swelling, Fatique
→ Characteristic Symptoms
Peripheral Oedema, JVP ↑ , Hepatomegaly
→ Signs of Congestion of Systemic Veins
S3 , Pulmonary Rales , Cardiac Murmur
E C G
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 34/180
E C G
A low Predictive Value
LAH and LVH May Be Associated wit LV Dysfunction Anterior Q-wave and LBBB a good predictors of EF ↓↓
Detecting Arrhytmias as Causative of HF
CHEST X-RAY
A Part of Initial Diagnosis of HF
→ Cardiomegaly, Pulmonary Congestion Relationship Between Radiological Signs and
Haemodynamic Findings may Depend on the Duration
and Severity HF
HAEMATOLOGY & BIOCHEMISTRY
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 35/180
HAEMATOLOGY & BIOCHEMISTRY
A Part of Routine Diagnostic
Hb, Leucocyte, Platelets Electrolytes, Creatinine, Glucose, Hepatic Enzyme,
Urinalysis
TSH, C-RP, Uric Acid
ECHOCARDIOGRAPHY
The Preferred Methods
Helpful in Determining the Aetiology
Follow Up of Patients Heart Failure
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 36/180
PULMONARY FUNCTIONS
A Little Value in Diagnosis Heart Failure Usefull in Excluding Respiratory Diseases
EXERCISE TESTING
Focused on Functional, Treatment Assessment and
Prognostic
STRESS ECHOCARDIOGRAPHY
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 37/180
STRESS ECHOCARDIOGRAPHY
For Detecting Ischaemia
Viability Study
NUCLEAR CARDIOLOGY
Not Recommended as a Routine Use
CMR ( CARDIAC MAGNETIC RESONANCE IMAGING)
Recommenmded if Other Imaging Techniques not
Provided Diagnostic Answer
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 38/180
INVASIVE INVESTIGATION
Elucidating the Cause and Prognostic Informations
Coronary Angiography :
in CAD’s Patients
Haemodynamic Monitoring :
To Assess Diagnostic and Treatment of HF
Endomyocardial Biopsy :
in Patients with Unexplained HF
NATRIURETIC PEPTIDES
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 39/180
NATRIURETIC PEPTIDES
Cardiac Function ↓↓ (LV Function ↓↓) →
↑↑ Plasma Natriuretic Peptide Concentration
(Diagnostic Blood Use for HF)
Natriuretic Peptide ↑↑ :
Greatest Risk of CV Events
Natriuretic Peptide ↓↓ :
Improve Outcome in Patients with
Treatment
Identify Pts. With Asymptomatic LV Dysfunction (MI, CAD)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 40/180
Suspected Heart Failure Because
of symptoms and signs
Assess Presence of Cardiac Disease by ECG, X-Rayor NatriureticPeptides (Where Available)
Imaging by Echocardiography (Nuclear Angiography or MRI Where Available)
Assess Etiology, Degree, PrecipitatingFactors and Type of Cardiac Dysfunction
Tests Abnormal
Tests Abnormal
Choose Therapy
ALGORITHM FOR THE DIAGNOSIS OF THE HF
If Normal Heart Failure
Unlikely
Additional Diagnosis TestsWhere Appropriate (e.g.Coronary Angiography)
If Normal Heart Failure
Unlikely
(ESC, 2001)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 41/180
Treatment of C H F
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 42/180
Aims of Treatment
1. Preventiona) Prevention and/or controlling of diseases leading
to cardiac dysfunction and heart failure
b) Prevention of progression to heart failure once
cardiac dysfunction is established2. Morbidity
Maintenance or improvement in quality of life
3. Mortality
Increased duration of life
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 43/180
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 44/180
ACC/AHA & EUROPE (ESC) 2001
GUIDELINES FOR THE MANAGEMENT
OF HEART FAILURE
ACE-inhibitor
→ Use as first line therapy
→ Should be up titrated to the dosages shown in the large
clinical trial, and not titrated based on symptomatic
improvement
DIURETIC → to control fluid overload
Β-BLOCKER
→ For all patients with stable mild-severe HF on
standard treatment
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 45/180
ACC/AHA & EUROPE (ESC) 2001
GUIDELINES FOR THE MANAGEMENT
OF HEART FAILURE
Aldosteron Receptor Antagonis
→ in advance HF ( NYHA III-IV )
DIGOXIN
→ in AF
→ May be added for symptom relief
ARB→ Considered in patients not tolerate ACE
inhibitors and not on β - blocker
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 46/180
Management Outline
Establish that the patient has HF.
Ascertain presenting features: pulmonary oedema, exertional
breathlessness, fatigue, peripheral oedema
Assess severity of symptoms
Determine aetiology of heart failure
Identify precipitating and exacerbating factors
Identify concomitant diseases
Estimate prognosis
Anticipate complications
Counsel patient and relatives
Choose appropriate management
Monitor progress and manage accordingly
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 47/180
TREATMENT
Correction of aggravating factors
MEDICATIONS
Endocarditis
Obesity
Hypertension
Physical activityDietary excess
Pregnancy
Arrhythmias (AF)
Infections
HyperthyroidismThromboembolism
Treatment opt ion s
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 48/180
Treatment opt ion s
Non-pharmacological management
General advice and measures
Exercise and exercise training
Pharmacological therapy
Angiotensin-converting enzyme (ACE) inhibitors
Diuretics
Beta-adrenoceptor antagonists
Aldosterone receptor antagonists
Angiotensin receptor antagonists
Cardiac glycosidesVasodilator agents (nitrates/hydralazine)
Positive inotropic agents
Anticoagulation
Antiarrhythmic agents
Oxygen
Devices and surgeryRevascularization (catheter interventions and surgery), other forms of surgery
Pacemakers
Implantable cardioverter defibrillators (ICD)
Heart transplantation, ventricular assist devices, artificial heart
Ultrafiltration, haemodialysis
Guidelines for the diagnosis and treatment of chronic heart failureEuropean Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 49/180
DRUGSHEMODYNAMIC EFFECTS
AI
A + V
V
D
Ventricular Filling Pressure
StrokeVolume
Normal
CHF
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 50/180
PHARMACOLOGIC THERAPY
DIURETICS
Improved
symptoms
Decreased
mortality
Prevention
of CHF
yes ? ?
Vasodil.(Nitrates) yes yes ?
DIGOXIN yes = minimal
INOTROPES yes mort. ?
Other neurohormonal
control drugsyes + / - ?
ACEI yes YES yes
Neurohumoral
Control
NO
yes
no
no
YES
YES
TREATMENT
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 51/180
TREATMENT
Normal
AsymptomaticLV dysfunctionEF <40%
Symptomatic CHFNYHA II
InotropesSpecialized therapyTransplant
Symptomatic CHFNYHA - IV
Symptomatic CHFNYHA - III
Secondary preventionModification of physical activity
ACEI
Diuretics mild Neurohormonal
inhibitorsDigoxin?
LoopDiuretics
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 52/180
Pharmacological therapy
Stages in the evolution of HF and recommended therapy by stage
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 53/180
Stage A Stage B Stage C Stage D
Pts with :
• Hypertension
• CAD
• DM
• Cardiotoxins
• FHx CM
THERAPY• Treat Hypertension
• Stop smoking
• Treat lipid disorders
• Encourage regular exercise
• Stop alcohol
& drug use
• ACE inhibition
Pts with :
• Previous MI
• LV systolic
dysfunction
• Asymptomatic
Valvular disease
THERAPY• All measures under
stage A
• ACE inhibitor
• Beta-blockers
THERAPY• All measures under
stage A
• Drugs for routine use:
• diuretic• ACE inhibitor
• Beta-blockers
• digitalis
THERAPY• All measures under
stage A,B and C
• Mechanical assist
device• Heart transplantation
• Continuous IV
inotrphic infusions for
palliation
Pts who have
marked symptoms
at rest despite
maximal medical
therapy.
Pts with :
• Struct. HD
• Shortness of
breath and fatigue,
reduce exercise
tolerance
Struct.
Heart
Disease
Develop
Symp.of
HF
Refract.
Symp.of
HF at rest
Stages in the evolution of HF and recommended therapy by stage
ACC/AHA Guidelines for theEvaluation and Management of Chronic Heart Failure in the Adult 2001
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 54/180
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 55/180
Angiotens in-con verting enzyme inhib i tors
Recommended as first-line therapy.
Should be uptitrated to the dosages shown to beeffective in the large, controlled trials, and nottitrated based on symptomatic improvement.
Moderate renal insufficiency and a relatively low bloodpressure (serum creatinine 250 µmol.l-1 and systolicBP 90 mmHg) are not contraindications.
Absolute contraindications: bilateral renal arterystenosis and angioedema.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 56/180
CO
PRELOAD AFTERLOAD
Normal Contractility
DiminishedContractility
Normal Contractility
DiminishedContractility
VV AV
VASODILATOR DRUGS
PRINCIPLES
VASODILATORS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 57/180
VenousVasodilatation
MIXED Calcium antagonistsa-adrenergic Blockers
ACEIAngiotensin II inhibitors
K+ channel activatorsNitroprusside
VENOUS Nitrates
Molsidomine
ARTERIAL Minoxidil
Hydralazine
VASODILATORS
CLASSIFICATION
ArterialVasodilatation
ACEI
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 58/180
VASOCONSTRICTION VASODILATATION
Kininogen
Kallikrein
Inactive Fragments
Angiotensinogen
Angiotensin I
RENIN
Kininase IIInhibitor
ALDOSTERONE
SYMPATHETIC
VASOPRESSIN
PROSTAGLANDINS
tPA
ANGIOTENSIN II
BRADYKININ
ACEI
MECHANISM OF ACTION
A.C.E.
ACEI
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 59/180
ACEI
HEMODYNAMIC EFFECTSArteriovenous Vasodilatation
- PAD, PCWP and LVEDP
- SVR and BP
- CO and exercise tolerance
No change in HR / contractility
MVO2
Renal, coronary and cerebral flow
Diuresis and natriuresis
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 60/180
75
95NoAdditionalTreatment
Necessary
(%)
Quinapril Heart Failure Trial
JACC 1993;22:1557
ACEI
FUNCTIONAL CAPACITY
Quinaprilcontinued
n=114
QuinaprilstoppedPlacebon=110
p<0.001
100
90
85
80
Weeks
Class II-III
161262 104 8 18 2014
ACEI
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 61/180
ACEI
ADVANTAGESInhibit LV remodeling post-MI
Modify the progression of chronic CHF
- Survival- Hospitalizations
- Improve the quality of life
In contrast to others vasodilators,do not produce neurohormonal activationor reflex tachycardia
Tolerance to its effects does not develop
ACEI
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 62/180
ACEI
UNDESIRABLE EFFECTSInherent in their mechanism of action
- Hypotension
- Hyperkalemia- Angioneurotic edema
Due to their chemical structure
- Cutaneous eruptions- Neutropenia,
thrombocytopenia
- Digestive upset
- Dry cough
- Renal Insuff.
- Dysgeusia
- Proteinuria
ACEI
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 63/180
ACEI
CONTRAINDICATIONS
Renal artery stenosis
Renal insufficiencyHyperkalemia
Arterial hypotension
Intolerance (due to side effects)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 64/180
ACE-Inhibitors in Asymptomatic Heart Failure
Development of symptomatic HF
Hospitalization of HF Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
SAVE & TRACE Study
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 65/180
ACE-Inhibitors in Symptomatic Heart Failure
All patients symptomatic Heart Failure should receive ACE-I.
A) No fluid retention , ACE-I should be given first.
B) With fluid retention , ACE-I + Diuretic
ACE-I : A) improves survival and symptoms.
B) reduces hospitalization.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 66/180
ACE INHIBITORS USED TO TREAT HEART FAILURE
DOSE RANGE TARGET DOSE FOR
DRUG (mg) FREQUENCY SURVIVAL BENEFIT*
Captopril 6.25 – 150 Three times daily 50 mg three times daily
Enalapril 2.5 – 20 Twice daily 10 mg twice daily
Lisinopril 2.5 – 40 Daily -
Ramipril 2.5 – 10 Once or twice daily 5 mg twice daily
Quinapril 5 – 20 Twice daily -
Zofenopril† - - 30 mg twice daily
Trandolapril† - - 4 mg daily
Imidapril HCl 5 – 10 Once daily 10 mg daily
* Target doses are those associated with increased survival in clinical trials
† This drug is not approved in the United States
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 67/180
ACEI SURVIVAL
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 68/180
Placebo
Enalapril
12111098765
PROBABILITY
OF
DEATH
MONTHS
0.1
0.8
0
0.2
0.3
0.7
0.4
0.5
0.6
p< 0.001
p< 0.002
CONSENSUS N Eng l J Med 1987;316:1429
ACEI SURVIVAL
43210
ACEI SURVIVAL
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 69/180
50
40
30
20
10
0
Months0 6 12
p = 0.30
2418 30 36 42 48
Enalapriln=2111
Placebon=2117
SOLVD (Prevention) N Eng l J Med 1992;327:685
%MORTALITY
ACEI SURVIVAL
n = 4228No CHF symptoms EF < 35
ACEI SURVIVAL
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 70/180
50
40
30
20
10
0
Months
0 6 12
p = 0.0036
%MORTALITY
2418 30 36 42 48
Enalapriln=1285
Placebon=1284
SOLVD (Treatment) N Eng l J M 1991;325:293
ACEI SURVIVAL
n = 2589
CHF- NYHA II-III- EF < 35
ACEI SURVIVAL
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 71/180
Mortality,%
4SAVE N Eng l J Med 1992;327:669
Years
30
20
10
01 2 3
Placebo
Captopril
0
n=1115
n=1116
p=0.019² -19%
ACEI SURVIVAL
n = 2231
3 - 16 days post AMIEF < 4012.5 --- 150 mg / day
Asymptomaticventricular
dysfunction post MI
ACEI
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 72/180
ISIS-4
GISSI-3
SAVE
SMILE
AIRE
ACEI Benefit Pt Selection
Captopril
Lisinopril
Captopril
Zofenopril
Ramipril
0.5 / 5 wk
0.8 / 6 wk
4.2 / 3.5 yr
4.1 / 1 yr
6 / 1 yr
All with AMI
All with AMI
EF < 40asymptomatic
Ant. AMI, No TRL
Clinical CHF
TRACE Trandolapril 7.6 / 3 yr Vent Dysfx / Clinical CHF
EF < 35
ACEI
SURVIVAL POST MI
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 73/180
2. DIURETICS
Diuret ics
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 74/180
Diuret ics
Essential for symptomatic treatment when
fluid overload is present and manifest.
Always be administered in combination
with ACE inhibitors if possible.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
DIURETICS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 75/180
Cortex
Medulla
Thiazides Inhibit active exchange of Cl-Na
in the cortical diluting segment of the
ascending loop of Henle
K-sparing Inhibit reabsorption of Na in thedistal convoluted and collecting tubule
Loop diuretics
Inhibit exchange of Cl-Na-K inthe thick segment of the ascendingloop of Henle
Loop of HenleCollecting tubule
DIURETICS
THIAZIDES
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 76/180
THIAZIDES
MECHANISM OF ACTIONExcrete 5 - 10% of filtered Na+
Elimination of KInhibit carbonic anhydrase:increase elimination of HCO3
Excretion of uric acid, Ca and Mg
No dose - effect relationship
LOOP DIURETICS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 77/180
LOOP DIURETICS
MECHANISM OF ACTIONExcrete 15 - 20% of filtered Na+
Elimination of K+
, Ca+
and Mg++
Resistance of afferent arterioles
- Cortical flow and GFR
- Release renal PGs
- NSAIDs may antagonize diuresis
K-SPARING DIURETICS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 78/180
K-SPARING DIURETICS
MECHANISM OF ACTION
Eliminate < 5% of filtered Na+
Inhibit exchange of Na+ for K+ or H+
Spironolactone = competitive
antagonist for the aldosterone receptor
Amiloride and triamterene blockNa+ channels controlled by aldosterone
DIURETIC EFFECTS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 79/180
Volume and preload
Improve symptoms of congestion
No direct effect on CO, butexcessive preload reduction may
Improves arterial distensibility
Neurohormonal activation
Levels of NA, Ang II and ARP
Exception: with spironolactone
DIURETIC EFFECTS
DIURETICS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 80/180
DIURETICS
ADVERSE REACTIONS Thiazide and Loop Diuretics
Changes in electrolytes:
VolumeNa+, K+, Ca++, Mg++ metabolic alkalosis
Metabolic changes:glycemia, uremia, goutLDL-C and TG
Cutaneous allergic reactions
DIURETICS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 81/180
DIURETICS
ADVERSE REACTIONSThiazide and Loop Diuretics
Idiosyncratic effects:
Blood dyscrasia, cholestatic jaundice andacute pancreatitis
Gastrointestinal effects
Genitourinary effects:Impotence and menstrual cramps
Deafness, nephrotoxicity(Loop diuretics)
DIURETICS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 82/180
DIURETICS
ADVERSE REACTIONSK-SPARING DIURETICS
Changes in electrolytes:
Na+, K+, acidosis
Musculoskeletal:
Cramps, weakness
Cutaneous allergic reactions :
Rash, pruritis
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 83/180
3. ALDOSTERONE
INHIBITORS
ALDOSTERONE INHIBITORS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 84/180
ALDOSTERONE
Retention Na+
Retention H2O
Excretion K+
Excretion Mg2+
Collagen
deposition
Fibrosis- myocardium
- vessels
Spironolactone
Edema
Arrhythmias
Competitive antagonist of the
aldosterone receptor
(myocardium, arterial walls, kidney)
ALDOSTERONE INHIBITORS
ALDOSTERONE INHIBITORS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 85/180
ALDOSTERONE INHIBITORS
INDICATIONS
FOR DIURETIC EFFECT
• Pulmonary congestion (dyspnea)
• Systemic congestion (edema)
FOR ELECTROLYTE EFFECTS
• Hypo K+, Hypo Mg+
• Arrhythmias
• Better than K+ supplements
FOR NEUROHORMONAL EFFECTS
• Please see RALES results,
N Engl J Med 1999:341:709-717
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 86/180
Recommended in advanced HF (NYHA III-IV),
in addition to ACE inhibition and diuretics to
improve survival and morbidity
Aldos terone recepto r antagon ists - sp ironolactone
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 87/180
The RALES mor tali ty tr ial
Low dose spironolactone (12.5 –50 mg) on top
of an ACE inhibitor and a loop diuretic improved survival of patients in advanced
heart failure (NYHA class III or IV).
Aldosterone receptor antagon is ts - spi ronolactone
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 88/180
4. ß-BlockersStart Low Go Slow
Activation and Blockade of Neurohumorali
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 89/180
System in CHF
RAA System SNS System
Angiotensin II Noradrenalin
Hypertroph y, apopto sis, isch aem ia,
arrhytm ia, remodel ing, f ibros is
β-BlockerACE-I
ADRENERGIC ACTIVATION
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 90/180
↑ CNS Sympathetic
Outflow
↑ Sympathetic
activity to kidneys
& blood vessels
↑ Cardiac
Sympathetic activity
β1-receptors β2-receptors a1-receptors
Mycocyte hypertrophy & death,
dilatation, ischaemia & arrhytmia’s
Vasoconstriction
Sodium Retention
Packer, AHA 2000
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 91/180
Why add-on β-blocker ,
if HF patient is already stable
on standard therapy with
ACE-I, diuretics ± digoxin
?
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 92/180
Benefits of “Add-on” β-Blocker
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 93/180
Short-term :
1. Improvement of symptoms (LVEF ↑)
2. Improvement of NYHA class
3. Improvement of daily activities
4.Reduction of hospitalization rate & length of
hospital stay (financial & psychological burden)
Long-term :
1.Slowing the progression of CHF
2. Increase of survival rate
A Clear Dose-Effect Relationship(MOCHA Study)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 94/180
(MOCHA Study)
Plc
0
1
2
3
4
5
6
78
LVEF (EF Units)
*
256.25 12.5
*
* *
mg bid
P < 0.001
- 30
0
30
60
90
* * *
mg bidPlc 6.25
* * *
% w
o r s e
% i m
p r o v e d
12.5 25
0
0.1
0.2
0.3
0.4
Hospitalization/Pts
* * *
* *
P = 0.01
Plc 256.25 12.5 mg bid 0
4
8
12
16
Mortality (%)
* * *
* *
P < 0.001
Plc 256.25 12.5 mg bid B
r i s t o w e t a l ( 1 9 9 6 )
Patient Global Assessment
COPERNICUS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 95/180
% S
u r v i v a l
0 0
3 6 9 12 15 18 21 Months
100
90
80
60
70
P=0.00013
Carvedilol
Placebo
CO CUS
All-cause mortality
COPERNICUS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 96/180
Favors treatment Favors placebo
0.50.25 0.75 1.251.0
All
patients
Recent orrecurrentdecompensation
Annual placebo mortality rate
(per patient-year)
19.7%
28.5%
0
Effect of carvedilol on mortality
Beta-adrenoceptor antagon ists
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 97/180
Recommended for the treatment of all ptswith stable, mild, moderate and severe heart
failure on standard treatment, unless there is
a contraindication.
Patients with LV systolic dysfunction, with or
without symptomatic HF, following an AMI
long-term betablockade is recommended in addition to ACE inhibitor.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
Beta-adrenoceptor antagon ists
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 98/180
CIB IS II, MERIT HF, US CARVEDILOL AND
COPERNICUS study
Reduction in total mortality, cardiovascular mortality, sudden death and death due to
progression of heart failure in patients in func.class II-IV.
reduces hospitalizations
improves the functional class and leads toless worsening of heart failure.
PHARMACOLOGICAL PROPERTIES OF
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 99/180
β-BLOCKING AGENT FOR HF
AGENT
β1-BLOKADE
β2-BLOKADE
a-
BLOKADE ISA
ANCILLARY
EFFECTS
Carvedilol + + + + + + + + + - + + +
Metoprolol + + + - - - -
Bisoprolol + + + - - - -
THE RECOMMENDED PROCEDURE FOR
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 100/180
STARTING β-BLOCKER
1. Patient should be on standard therapy
(ACE inhibitor +/- diuretic)
2. Patient in stable conditions
No iv inotropic therapy
Without signs of marked fluid retention
3. Start initial low doses and titrate to maintenance dose
(the dose may be doubled every 1 – 2 weeks)
(ESC.Gu idelines fo r HF, 2001)
DOSES OF β-BLOCKER
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 101/180
β BLOCKER FIRST DOSE TARGET DOSE TITRATION
PERIOD
Bisoprolol 1.25 mg 10 mg Weeks – Month
Metoprolol
Tartrate
5 mg 150 mg Weeks – Month
Metoprolol
Succinate
12.5 mg 200 mg Weeks – Month
Carvedilol 2 x 3.125 mg 2 x 25 mg Weeks – Month
(Euro pean Heart Jou rnal, vo l. 22, Sept. 2001)
CONTRAINDICATIONS OF
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 102/180
β-BLOCKER IN PATIENT H F
Asthma Bronchial
Severe Bronchial Desease
Symptomatic Bradycardia and
Hypotension
INTOLERANCE OF β-BLOCKER
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 103/180
INTOLERANCE OF β-BLOCKER
Symptomatic
Bradycardia
Worsening HF Hypotension
How to Handle Intolerance
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 104/180
SYMPTOMATIC BRADYCARDIA
Check Blood Digoxin and/or reduce
other AV nodus inhibiting drugs
Reduces β-Blocker dose
or if necessary stop it
Consider implantation of
peacemaker
How to Handle Intolerance
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 105/180
WORSENING HF
Increase dose of Diuretics
Reduces β-Blocker dose
or if necessary stop it
If indicated, give inotropic drugs or nitroprusside or nitroglycerin
How to Handle Intolerance
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 106/180
HYPOTENSION
Reduces ACE-I or
vasodilator
Take β-Blocker :
After meal
At different time than ACE-I
Reduces dose or if necessary stop it
β-BLOCKER IN HIGH RISK GROUPS PTS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 107/180
β
WITH CHF
Elderly Patient
Type 2 Diabetes Mellitus
Renal Failure
Digitalis / Aldosteron Antagonist /
Amiodaron
(Pos t-Hoc Analys is o f the CIB IS II)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 108/180
5. Angiotensin II receptor
antagonists
ANGIOTENSIN II INHIBITORS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 109/180
MECHANISM OF ACTION
RENIN
Angiotensinogen Angiotensin I
ANGIOTENSIN II
ACE
Other paths
Vasoconstriction Proliferative Action
Vasodilatation Antiproliferative Action
AT1 AT2
AT1RECEPTORBLOCKERS
RECEPTORS
AT1 RECEPTOR BLOCKERS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 110/180
DRUGS
Losartan
ValsartanIrbersartan
Candesartan
Competitive and selective
blocking of AT1 receptors
Angiotensin II recepto r antagonists
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 111/180
ARBs could be considered in patients who do nottolerate ACE inhibitors for symptomatictreatment.
It is unclear whether ARBs are as effective as ACE inhibitors for mortality reduction.
In combination with ACE inhibition, ARBs may
improve heart failure symptoms and reducehospitalizations for worsening heart failure.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
Angiotensin II recepto r antagonists
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 112/180
VAL-H
Patients were randomized to placebo or valsartan on top of standard therapy.
The results showed no difference in overallmortality, but a reduction in the combined end-point all-cause mortality or morbidity
expressed as hospitalization because of worsening heart failure.
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 113/180
6. Cardiac glycosides
DIGOXIN
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 114/180
Na+
K+
K+
Na+
Na+ Ca++
Ca++
Na-K ATPase Na-Ca Exchange
Myofilaments
DIGOXIN
CONTRACTILITY
DIGOXIN
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 115/180
PHARMACOKINETIC PROPERTIES
Oral absorption (%)
Protein binding (%)
Volume of distribution (l/Kg)
Half life
EliminationOnset (min)
i.v.
oral
Maximal effect (h)
i.v.
oral
Duration
Therapeutic level (ng/ml)
60 - 75
25
6 (3-9)
36 (26-46) h
Renal
5 - 30
30 - 90
2 - 4
3 - 6
2 - 6 days
0.5 - 2
DIGOXIN
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 116/180
DIGITALIZATION STRATEGIES
(mg)
0.125-0.5 / d
0.25 / d
i.v
0.5 + 0.25 / 4 h
ILD: 0.75-1
oral 12-24 h
0.75 + 0.25 / 6 h
1.25-1.5
oral 2-5 d
0.25 / 6-12 h
1.5-1.75
Loading dose (mg)Maintenance
Dose
ILD = average INITIAL dose required for digoxin loading
DIGOXIN
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 117/180
HEMODYNAMIC EFFECTSCardiac output
LV ejection fraction
LVEDP
Exercise tolerance
Natriuresis
Neurohormonal activation
DIGOXIN
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 118/180
NEUROHORMONAL EFFECTS
Plasma Noradrenaline
Peripheral nervous system activityRAAS activity
Vagal toneNormalizes arterial baroreceptors
DIGOXIN
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 119/180
%WORSENING
OF CHFp = 0.001DIGOXIN: 0.125 - 0.5 mg /d
(0.7 - 2.0 ng/ml)EF < 35%Class I-III (digoxin+diuretic+ACEI)
Also significantly decreased exercisetime and LVEF.
EFFECT ON CHF PROGRESSION
RADIANCEN Eng l J Med 1993;329:1
Placebo n=93DIGOXINWithdrawal
DIGOXIN n=85
30
10
0
20
10080200 40 60
Days
OVERALL MORTALITY
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 120/180
50
40
30
20
10
0
Placebon=3403
DIGOXINn=3397
480 12 24 36
%
DIG N Eng l J Med 1997;336:525 Months
p = 0.8
DIGOXIN
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 121/180
LONG TERM EFFECTS
Survival similar to placebo
Fewer hospital admissions
More serious arrhythmias
More myocardial infarctions
DIGOXIN
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 122/180
CLINICAL USES
AF with rapid ventricular response
CHF refractory to other drugs
Other indications?
Can be combined with other drugs
DIGOXIN
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 123/180
CONTRAINDICATIONSABSOLUTE:- Digoxin toxicity
RELATIVE
- Advanced A-V block without pacemaker
- Bradycardia or sick sinus without PM
- PVC’s and TV
- Marked hypokalemia
- W-P-W with atrial fibrillation
DIGOXIN TOXICITY
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 124/180
CARDIAC MANIFESTATIONS
ARRHYTHMIAS :
- Ventricular (PVCs, TV, VF)
- Supraventricular (PACs, SVT)
BLOCKS:
- S-A and A-V blocks
CHF EXACERBATION
DIGOXIN TOXICITY
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 125/180
EXTRACARDIAC MANIFESTATIONSGASTROINTESTINAL:
- Nausea, vomiting, diarrhea NERVOUS:
- Depression, disorientation, paresthesias
VISUAL:
- Blurred vision, scotomas and yellow-greenvision
HYPERESTROGENISM:- Gynecomastia, galactorrhea
Cardiac glycos ides
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 126/180
indicated in atrial fibrillation and any degree of
symptomatic heart failure.
A combination of digoxin and beta-blockadeappears superior than either agent alone.
In sinus rhythm, digoxin is recommended toimprove the clinical status of patients with
persisting heart failure despite ACE inhibitor anddiuretic treatment.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
Cardiac glycos ides
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 127/180
DIG tr ial
Long-term digoxin did not improve survival.
The primary benefit and indication for digoxinin heart failure is to reduce symptoms and
improve clinical status decrease the risk of
hospitalization for heart failure without an
impact on survival.
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 128/180
7. Vasodilator agents
N ifi l f dil t i th t t t f HF
Vasodi lator agents in chronic heart failure
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 129/180
No specific role for vasodilators in the treatment of HF
Used as adjunctive therapy for angina or concomitant
hypertension.
In case of intolerance to ACE inhibitors ARBs are
preferred to the combination hydralazine –nitrates.
HYDRALAZINE-ISOSORBIDE DINITRATE
Hydralazine (up to 300 mg) in combination with ISDN (up to 160
mg) without ACE inhibition may have some beneficial effect on
mortality, but not on hospitalization for HF.
Nitrates may be used for the treatment of concomitant angina or
relief of acute dyspnoea.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 130/180
8. Positive inotropic therapy
POSITIVE INOTROPES
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 131/180
CARDIAC GLYCOSIDES
SYMPATHOMIMETICS
Catecholaminesß-adrenergic agonists
PHOSPHODIESTERASE INHIBITORSAmrinoneEnoximone
Others
Milrinone
Piroximone
ß-ADRENERGIC STIMULANTS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 132/180
CLASSIFICATION
B1 StimulantsInc rease contract i l i ty
Dobutamine Doxaminol Xamoterol
Butopamine Prenalterol Tazolol
B2 StimulantsProdu ce arter ial vasodi latat ion and reduce SVR
PirbuterolCarbuterolRimiterolFenoterol TretoquinolSalbutamolTerbutalineSalmefamolSoterenolQuinterenol
MixedDopamine
DOPAMINE AND DOBUTAMINE
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 133/180
EFFECTS
Receptors
Contractility
Heart Rate
Arterial Press.Renal perfusion
Arrhythmia
DA (µg / Kg / min) Dobutamine
< 2
DA1 / DA2
±
±
±++
-
2 - 5
ß1
++
+
++
±
> 5
ß1 + a
++
++
++±
++
ß1
++
±
+++
±
POSITIVE INOTROPES
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 134/180
CONCLUSIONS
May increase mortality
Safer in lower doses
Use only in refractory CHF
NOT for use as chronic therapy
Posi t ive ino trop ic therapy
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 135/180
Commonly used to limit severe episodes of
HF or as a bridge to heart transplantation in end-stage HF.
Repeated or prolonged treatment with oral
inotropic agents increases mortality.
Currently, insuffcient data are available torecommend dopaminergic agents for heartfailure treatment.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
Posi t ive ino trop ic therapy
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 136/180
POSITIVE INOTROPHIC AGENTS
DobutaminMilrinone
Levosimendan
DOPAMINERGIC AGENTSIbopamine is not recommended for the treatment of
chronic HF due to systolic LV dysfunction.
Intravenous dopamine is used for the sort-term
correction of haemodynamic disturbances of severeepisodes of worsening HF.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 137/180
9. Antiarrhythmics
ANTIARRHYTHMICS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 138/180
Sustained VT, with/without symptoms
- ß Blockers
- AmiodaroneSudden death from VF
- Consider
implantabledefibrillator
ANTIARRHYTHMICS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 139/180
MORTALITY
EMIAT Am Coll Cardiol 1996
13.6 13.7
Placebo Amiodarone0
5
10
15
101 / 743 102 / 743
MORTALITY
AT 2 YEARS%
n=14865-21d post MIAmiodarone200 mg/dFollow up 1 - 4 years
ns
N i di ti f th f ti h th i t i HF
Ant iarrhythmics
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 140/180
No indication for the use of antiarrhythmic agents in HF
Indications for antiarrhythmic drug therapy include AF(rarely flutter), non-sustained or sustained VT.
CLASS I ANTIARRHYTHMICS
should be avoided
CLASS II ANTIARRHYTHMICS
Beta-blockers reduce sudden death in heart failure
CLASS III ANTIARRHYTHMICS
Amiodarone is the only antiarrhythmic drug withoutclinically relevant negative inotropic effects.
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 141/180
10. Anticoagulation
11. Antiplatelet Drugs
ANTICOAGULANTS
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 142/180
PREVIOUS EMBOLIC EPISODEATRIAL FIBRILLATION
Identified thrombus
LV Aneurysm (3-6 mo post MI)Class III-IV in the presence of:
- EF < 30
- Aneurysm or very dilated LVPhlebitis
Prolonged bed rest
Ant icoagulat ion
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 143/180
Recommendation
1. All pts with HF and AF should be treated with
warfarin unless contraindicated.
2. Patients with LVEF 35% or less.
HFSA Guidelines for Management of Patients With Heart Failure Caused by Left
Ventricular Systolic Dysfunction - Pharmacological Approaches 2000
Antip latelet Drugs
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 144/180
Recommendation
There is insufficient evidence concerning thepotential negative therapeutic interaction between ASA and ACE inhibitors.
Antiplatelet agent for pts with HF who haveunderlying CAD.
HFSA Guidelines for Management of Patients With Heart Failure Caused by Left
Ventricular Systolic Dysfunction - Pharmacological Approaches 2000
Chron ic heart fai lure — cho ice of
pharmacological therapy A
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 145/180
LV systolic dysfunction ACE inhibitor Diuretic Beta-blocker AldosteroneAntagonist
Asymptomatic LV
dysfunctionIndicated Not indicated Post MI Not indicated
Symptomatic HF (NYHA II) Indicated
Indicated if
Fluid retention Indicated Not indicated
Worsening HF (NYHA III-IV) IndicatedIndicated
comb. diuretic
IndicatedIndicated
End-stage HF (NYHA IV) Indicated
Indicated
comb. diuretic
Indicated
Indicated
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
Chron ic heart failure — cho ice of
pharmacological therapy B
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 146/180
LV systolic dysfunction
Angiotensin
II receptor
antagonists
Cardiac glycosides
Vasodilator
(hydralazine/
isosorbide
dinitrate)
Potassium -sparing
diuretic
Asymptomatic LV
dysfunctionNot indicated With AF Not indicated Not indicated
Symptomatic HF (NYHA II)
If ACE inhibitors
are not tolerated
and not on beta-
blockade
(a) when AF
(b) when improved
from more severe
HF in sinusrhythm
If ACE inhibitors
and angiotensin
II antagonists
are not
tolerated
If persisting
hypokalaemia
Worsening HF (NYHA III-IV)
If ACE inhibitors
are not tolerated
and not on beta-
blockade
indicated
If ACE inhibitors
and angiotensin
II antagonists
are not
tolerated
If persisting
hypokalaemia
End-stage HF (NYHA IV) If ACE inhibitorsare not tolerated
and not on beta-
blockade
indicated
If ACE inhibitors
and angiotensinII antagonists
are not
tolerated
If persistinghypokalaemia
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 147/180
Intervention
RevascularizationSurgical
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 148/180
Pts with heart failure of ischaemic origin revascularization symtomatic improvement.
A strong negative correlation of operative mortality and LVEF,
a low LVEF (<25%) was associated with increased
operative mortality. Advance HF symptoms (NYHA IV)
resulted in a greater mortality rate.
Off pump coronary revascularization may lower the surgical
risk for HF.
Heart Transplantation is an accepted mode of treatment for
end-stage HF.
Non Surgical
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
Care and Follow-up
R d d t f
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 149/180
Recommended components of programs
use a team approachvigilant follow-up, first follow-up within 10 days of discharge
discharge planning
increased access to health careoptimizing medical therapy with guidelines
intense education and counselling inpatient andoutpatient
strategies address barriers to compliance
early attention to signs and symptoms
flexible diuretic regimen
Guidelines for the diagnosis and treatment of chronic heart failure
European Heart Journal (2001) 22, 1527-1560
Future treatment
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 150/180
1. Sympathetic nervous system
2. The RAA system3. Atrial and brain natriuretic peptides
4. Arginin vasopressin
5. Endothelin
6. Growth hormone
7. Calcitonin gene related peptide
Neurohormonal modulation
Cardiac reparation: fixing the heartwith cells, new vessels and genes (1)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 151/180
1. Multiplication of residual myocytes(forcing the cells to enter mytotic cycle)
2. Transforming fibrablasts in the scar
3. Implanting exogenous contractiles cells(foetal cardiomyocites, skeletalmyoblasts, stem cells)
Aims: to repopulate fibrous scars with new
contractile cells
Cell based
interventions
Eur Heart J 2002;4: D73-81
CON’T (2)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 152/180
1. Administration of angiogenic growth factors
VEGF, basic FGF
2. Problems: nature of compound , dose,
route, and adverse events (abnormal bloodvessels, proliferative retinopathy, etc)
AngiogenesisAims: to provides new blood supply to
the diseased heart
Eur Heart J 2002;4: D73-81
CON’T(3)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 153/180
1. Gene manipulation of 3 majors areas: Ca
handling, beta-adenergic signalling and
apoptosis
2. Inducing expression of silent genes
Gene therapy
Aims: to improve the function of the failing
heart
Safety problems: control of targeted proteinexpression, inflammation, autoimmunity
and oncogenesis (basically irreversible)
Eur Heart J 2002;4: D73-81
Dual-chamber pacemakers arebeneficial
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 154/180
•Drug-resistant CHF
• Intact sinus rhythm
• Absence of chronic atrial dysrhythmias
• EF <20%
• Viable myocardium
• No or stable angina
• DMC and PR >, MR and TR, QRS >, QRS
PR + QRS > 350 ms.• QRS >140 ms, MR > 450 ms, and LV filling
time <200 ms
• HOCM
Cardiac resynchronizationtherapy
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 155/180
py• Reason:
Patients with CHF frequently exhibitedQRS prolongation with diseaseprogression. The delayed ventricular
activation leads to asynchronousventricular contraction with negativeeffects on LV performance
• Aim:
To normalize AV activation sequenceand disturbed ventricular contractionpatterns
Cardiac resynchronizationtherapy
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 156/180
StudyNYHA QRS (ms) EF (%)
0 mo 3 mo 0 mo 3 mo 0 mo 3 mo
Path-CHF
(n=42)
3.0 2.0 - - - -
In Sync(n=81)
3.4 2.2 179 143 21 24
Alouco
(n=26)
3.3 2.0 179 159 - -
MUSTIC(n=67)
- - 176 - 23 -
J Inv Cardiol 2002; 14: 48-53
Resume
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 157/180
Pharmacological Treatment :
I. Asymptomatic Systolic LV dysfunction :• ACE Inhibitor
• -Blocker (in CAD)
II. Symptomatic Systolic LV dysfunction
A. No fluid retention ACE Inhibitor
-Blocker
If ischaemia (+) nitrate / revascularization
B. Fluid retention
Diuretic
ACE Inhibitor (ARBs if not tolerated)
-Blocker
± Digitalis
Resume
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 158/180
III. Worsening HF
Standard treatment : ACE Inhibitor, -Blocker Diuretic : doses + loop diuretic
Low dose spironolactone
Digitalis
Consider :
» Revascularization
» Valve surgery
» Heart transplant
IV. End-stage HF
Intermittent inotrophic support
Circulatory support (IABP, Ventr.Assist Devices)Haemofiltration on dialysis
briddging to heart transplantation
Conclusion
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 159/180
Management of HF must be starting fromthe earlier stage (AHA/ACC stage A).
Treatment at each stage can reduce
morbidity and mortality.
Before initiating therapy :
Established the correct diagnose.
Consider management outline.
Conclusion
Non pharmacolgical intervention are helpfull in :
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 160/180
Non pharmacolgical intervention are helpfull in :
improving quality of lifereducing readmission
lowering cost.
Organize multi-disciplinary care :
HF clinic, HF nurse specialist, pts telemonitoring.
Health care system.
To optimize HF management
Treatment should be according to the Guidelines,intensive education, and behavioral change efforts.
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 161/180
Thank YoU
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 162/180
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 163/180
DIASTOLIC HEART
FAILURE
SCOPE OF THE PROBLEM
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 164/180
• Epidemiological studies of HF havesuggested that 30-50% of cases of HF
have preserved LV systolic function.
• DHF has mortality rate equal assystolic heart failure
• No guideline yet regarding the
treatment of DHF
Greenberg & Hermann 2004
Defining Diastolic Heart Failure
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 165/180
• Diastolic dysfunction refers to a condition in which
abnormalities in mechanical function are presenting
during diastole.
•
Diastolic dysfunction is a condition in which higher than normal LV filling pressure are needed to maintain
a normal cardiac output.
• Diastolic heart failure is a clinical syndrome
characterized by the symptoms and signs of heartfailure, a preserved EF and abnormal diastolic
function.
(Vasan & Levy 2000)
Normal diastolic
function
Mild diastolic
dysfunction
Pseudonormal
stage
Restrictive-
filling stage
Echo-Doppler and Diastolic Dysfunction
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 166/180
function dysfunction stage filling stage
Left ventricular relaxation Normal
Left ventricular stiffness Normal
Left atrial contractility Normal Normal
Preload Normal Normal
Electrocardiogram
Mitral flow
Pulmonary venousflow
E wave
A wave
QRST P
Diastole
Systole
Atrial reversal
( Garcia, 2000 )
Diastolic Heart Failure : Effects of
Age on Prevalence and Prognosis
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 167/180
Age, y
<50 50-70 >70
Prevalence 15 33 50
Mortality 15 33 50
Morbidity 25 50 50
( Zile & Brutsaert, 2002 )
CHARACTERISTICS
Age
Sex
DIASTOLIC HEART
FAIURE
Frequently elderly
Frequently female
SYSTOLIC HEART
FAILURE
All ages,typically 50-70 yr
More often male
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 168/180
Sex
Left ventricle EF
Left ventricle cavity size
LVH on echo
Chest radiography
Gallop rhythm present
Coexisting conditions
Hypertension
Diabetes mellitus
Previous MCI
Obesity
Chronic lung disease
Sleep apnea
Long term dialysis
Atrial fibrillation
Frequently female
Preserved or normal (+ > 40%)
Usually normal,often LVH
concentric
Usually present
Congestion with/out cardiomegali
Fourth heart sound
+++
+++
+
+++
++
++
++
+
Usually paroxismal
More often male
Depressed,+ < 40%
Usually dilated
Sometimes present
Congestion & cardiomegali
Third heart sound
++
++
+++
+
0
++
0
+
Usually persistent(NEJM 2003)
Conditions Associated with Diastolic
Dysfunction
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 169/180
Condition
Coronary artery disease
Hypertensive heart disease
Valvular heart disease
Normal aging
Hypertrophic cardiomyopathy
Infiltrative disease of the
myocardium
(amyloid,sarcoid,haemocromatosis,
lympoma)
Possible Contributory Mechanism :
Asynchronous myocardial relaxation
secondary,to ischemia or scar and
altered mechanical loading
LVH
AS leading to LVH , MS leading to reduced
filling
Impaired early filling due to reduced
compliance with associated increase in late
filling
Hypertrophy,fibrosis, and asynchronous
regional lengthening, hence impairedrelaxation.
Reduced LVED distensibility (increased
LVEDP)
(Vasan & Levy 1998)
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 170/180
(Mandinov,Eberli,Seiler,Hess.Cardiosvasc Res 2000)
Diagnostic Criteria for Diastolic Heart Failure
Signs or symptoms of congestive heart failure
Exertional dyspnoea [eventually objective evidence by reduced peak exercise oxygen consumption(<25 ml.kg-1.min-1)], orthopnea, gallop sounds, lung crepitations, pulmonary oedema
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 171/180
( European Study Group on DHF, 1998 )
and
Normal or mildly reduced left ventricular systolic function:
LVEF45% and LVEDIDI<3.2 cm.m-2 or LVEDVI<102 ml.m-2
and
Evidence of abnormal left ventricular relaxation, filling, diastolic distensibility and diastolic stiffness:
Slow isovolumic left ventricular relaxation:
LVdP/dtmin <1100 mmHg.s-1
and/or IVRT<30y>92 ms, IVRT30-50y>100 ms, IVRT>50y>105 ms
and/or >48 ms
and/or slow early left ventricular filling:PFR<160 ml.s-1.m-2
and/or PFR<30y<2.0 EDV.s-1, PFR30-50y<1.8 EDV.s-1, PFR>50y<1.6 EDV.s-1
and/or E/A<50y<1.0 and DT<50y>220 ms, E/A>50y<0.5 and DT>50y>280 ms
and/or S/D<50y>1.5, S/D>50y>2.5
and/or reduced left ventricular diastolic distensibility:
LVEDP>16 mmHg or mean PCW>12 mmHg
and/or PV A Flow > 35 cm.s-1
and/or PV A t>MV A t+ 30 ms
and/or A/H>0.20
and/or increased left ventricular chamber or muscle stiffness:
b>0.27
and/or b’>16
Criteria for Definite DHF
Criterion Objective Evidence
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 172/180
Definite evidence of CHF
AND
Objective evidence of normal LVsystolic function in proximity to
the CHF event
AND
Objective evidence of LV diastolicdysfunction
Includes clinical symptoms and signs, supporting
laboratory tests (such as chest X-ray), and a typicalclinical response to treatment with diuretics, with or
without documentation of elevated LV filling pressure
(at rest, on exercise, or in response to a volume load)
or a low cardiac index
Abnormal LV relaxation /filling/distensibility indices on
cardiac catheterization
LV EF > 0.50 within 72 h of event
( Vasan & Levy, 2000 )
Criteria for Probable DHF
Criterion Objective Evidence
Definitive evidence of CHF Includes clinical symptoms and signs, supporting laboratory tests
(such as chest X-ray), and a typical clinical response to treatment
with diuretics with or without documentation of elevated LV filling
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 173/180
Objective evidence of normal LV systolic
function in proximity to the CHF event
Objective evidence of LV diastolic
dysfunction is lacking
AND
BUT
with diuretics, with or without documentation of elevated LV filling
pressure (at rest, on exercise, or in response to a volume load) or a
low cardiac index
LV EF > 0.50 within 72 h of CHF event
No conclusive information on LV diastolic function
Criteria for Possible DHF
Criterion Objective Evidence
Definitive evidence of CHF
Objective evidence of normal LV systolic
function, but not at the time of the CHF event
Objective evidence of LV diastolic dysfunction
is lacking
Includes clinical symptoms and signs, supporting laboratory test (such
as chest X-ray), and a typical clinical response to treatment with
diuretics, with or without documentation of elevated LV filling pressure
(at rest, on exercise, or in response to a volume load) or a low cardiac index
LV EF > 0.50
No conclusive information on LV diastolic function
AND
AND
( Vasan & Levy, 2000 )
Other Methods in diagnosing DHF
• Plasma Brain Natriuretic Peptide
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 174/180
• Plasma Brain Natriuretic Peptide
• Doppler tissue imaging
• Magnetic resonance imaging
• Radionuclide angiography
• Cardiac catheterization
Greenberg & Hermann 2004
Treatment of Diastolic Heart Failure
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 175/180
• Clinical investigations in relatively small
groups of patients• Clinical experience
• Concepts based on pathophysiology
mechanisms
The guidelines are based on :
Treatment of Diastolic Heart failure
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 176/180
Treatment of Diastolic Heart failure
• symptom targeted treatment
• disease / pathological targeted treatment
• the underlying mechanism targeted
treatment
( Zile & Brutsaert, 2002 )
Diastolic Heart Failure: Treatment
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 177/180
Symptom targeted treatment
Decrease pulmonary venous pressure
Reduce LV volumeMaintain atrial contraction
Prevent tachycardia
Improve exercise tolerance
Use positive inotropic agents with caution( Zile & Brutsaert, 2002 )
Diastolic Heart Failure: Treatment
N h l i l t t t
Symptom targeted treatment
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 178/180
Nonpharmacological treatment
Restrict sodium to prevent volume overload
Restrict fluid to prevent volume overload
Perform moderate aerobic exercise to improve cardiovascular
conditioning, decrease heart rate and maintain skeletal muscle
function
Pharmacological treatment
Diuretics including loop diuretics thiazides, spironolactone
Long-acting nitrates, -Adrenergic blockers
Calcium channel blockers
Renin angiotensin-aldosterone antagonists including ACE
inhibitors, angiotensin II receptor blockers and aldosterone
antagonists ( Zile & Brutsaert, 2002 )
Disease-targeted treatment
Prevent/treat myocardial ischemia
Diastolic Heart Failure
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 179/180
Prevent/treat myocardial ischemia
Prevent/regress ventricular hypertrophy
Mechanisms targeted treatment
Modify myocardial and extramyocardial mechanisms
Modify intracellular and extracellular mechanisms
An ideal therapeutic agent.
- Should target the underlying mechanisms
- Improve calcium homeostasis and energetics
- Blunt neurohumoral activation
- Prevent and regress fibrosis( Zile & Brutsaert, 2002 )
Trials of Diastolic Heart Failure
Trial Comparison Follow-up (n) Diagnostic Criteria
for DHF
Other Important
Inclusion/ Exclusion
Main Outcomes
7/27/2019 All about CHF.ppt
http://slidepdf.com/reader/full/all-about-chfppt 180/180
Criteria
PEP-CHF
CHARM-2
I-PRESERVE
SENIORS
(diastolic subset)
Hong Kong
SWEDIC
Placebo
Perindopril
Placebo
Candesartan
Placebo
IrbesartanPlacebo
Nebivolol
Placebo
Ramipril
Irbesartan
Placebo
Carvedilol
1.000
Minimum 18 months
2.500
Minimum 24 months
3.600
Approx 48 months2.000
(% DHF uncertain)
450
Minimum 12 months
140
9 months
3 of 9 clinical and
2 of 4 echocardiographic
criteria
EF > 40%
EF > 45%
EF > 35% and a cardiac
abnormality
Doppler criteria
Doppler criteria
Age > 70 years
Diuretics
Hospital admission in last
3 months
None
Clinical diagnosis of HF
Aged > 70 years
Hospital admission within
last 12 months
Diuretics
AF excluded
Death or HF-related
hospitalization
Death or hospitalization
for HF
Death and hospitalization
cardiovascular disease
Death or hospitalization
for HF
Quality of life 6-minute
walk test
Regression of diastolic
dysfunction